Clinical Trials Browser

Interventional × Invasive Bladder Cancer × tremelimumab × Clear all

NCT03702179 2024-12-05

IMMUNOPRESERVE

Phase 2 Completed

32 enrolled 19 charts

Invasive Bladder Cancer